R H H Groenwold1, E Hak, A W Hoes. 1. Julius Center for Health Sciences and Primary Care, University Medical center Utrecht, The Netherlands. r.h.h.groenwold@umcutrecht.nl
Abstract
OBJECTIVE: In nonrandomized intervention studies unequal distribution of patient characteristics in the groups under study may hinder comparability of prognosis and therefore lead to confounding bias. Our objective was to review methods to control for observed confounding, as well as unobserved confounding STUDY DESIGN AND SETTING: We reviewed epidemiologic literature on methods to control for observed and unobserved confounding. RESULTS: Various methods are available to control for observed (i.e., measured) confounders, either in the design of data collection (i.e., matching, restriction), or in data analysis (i.e., multivariate analysis, propensity score analysis). Methods to quantify unobserved confounding can be categorized in methods with and without prior knowledge of the effect estimate. Without prior knowledge of the effect estimate, unobserved confounding can be quantified using different types of sensitivity analysis. When prior knowledge is available, the size of unobserved confounding can be estimated directly by comparison with prior knowledge. CONCLUSION: Unobserved confounding should be addressed in a quantitative way to value the inferences of nonrandomized intervention studies.
OBJECTIVE: In nonrandomized intervention studies unequal distribution of patient characteristics in the groups under study may hinder comparability of prognosis and therefore lead to confounding bias. Our objective was to review methods to control for observed confounding, as well as unobserved confounding STUDY DESIGN AND SETTING: We reviewed epidemiologic literature on methods to control for observed and unobserved confounding. RESULTS: Various methods are available to control for observed (i.e., measured) confounders, either in the design of data collection (i.e., matching, restriction), or in data analysis (i.e., multivariate analysis, propensity score analysis). Methods to quantify unobserved confounding can be categorized in methods with and without prior knowledge of the effect estimate. Without prior knowledge of the effect estimate, unobserved confounding can be quantified using different types of sensitivity analysis. When prior knowledge is available, the size of unobserved confounding can be estimated directly by comparison with prior knowledge. CONCLUSION: Unobserved confounding should be addressed in a quantitative way to value the inferences of nonrandomized intervention studies.
Authors: Md Jamal Uddin; Rolf H H Groenwold; Mohammed Sanni Ali; Anthonius de Boer; Kit C B Roes; Muhammad A B Chowdhury; Olaf H Klungel Journal: Int J Clin Pharm Date: 2016-04-18
Authors: David Evans; Basile Chaix; Thierry Lobbedez; Christian Verger; Antoine Flahault Journal: BMC Med Res Methodol Date: 2012-10-11 Impact factor: 4.615
Authors: Nancy E Mayo; Mark Bayley; Pierre Duquette; Yves Lapierre; Ross Anderson; Susan Bartlett Journal: BMC Neurol Date: 2013-06-28 Impact factor: 2.474
Authors: Pushpa M Jairam; Pim A de Jong; Willem P T h M Mali; Ivana Isgum; Harry J de Koning; Carlijn van der Aalst; Matthijs Oudkerk; Rozemarijn Vliegenthart; Yolanda van der Graaf Journal: PLoS One Date: 2013-06-20 Impact factor: 3.240
Authors: Frans H Rutten; Rolf H H Groenwold; Alfred P E Sachs; Diederick E Grobbee; Arno W Hoes Journal: PLoS One Date: 2013-06-19 Impact factor: 3.240